Topic

Articles

Time sure flies, except when you are waiting for something to happen.

It’s Time to Listen to Science

FDA/FTC collaborate to end false and misleading statements and discuss the future of biosimilars at March 2020 public workshop on a competitive marketplace for biosimilars.

Commentary: A Competitive Marketplace for Biosimilars

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

How Fast Is Too Fast?

Siegfried Schmitt, PhD, is principal consultant withÂ PAREXEL, Siegfried.Schmitt@parexel.com.

Having a better understanding about compliance will be of benefit when looking for a job or for furthering one’s career, says Siegfried Schmitt, PhD, vice-president, technical, Parexel Consulting.


Starting a Career in the Bio/Pharmaceutical Industry

Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.


The Design Driver for Biosimilar Adoption

Characterizing and controlling protein aggregation is vital to ensure safety and efficacy of a biopharmaceutical product. In this interview, important aspects of protein aggregation and the tools available to address this issue are discussed.


Keeping Aggregation Under Control

Emergency actions to protect patients and the drug supply may have long-term implications.

Coronavirus Response: Reaction or New Reality?

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.


The Call for a Rapid Response

Nearly four decades after the first diagnosis, the fight to treat HIV/AIDs continues.

Fighting the Good Fight

FDA report says drug shortages are underappreciated and patients pay a price.

Viewpoints